180476-36-2 Usage
Description
3-Tridecylhexadecanoic Acid, a derivative of 14-Heptacosanone (H268520), is a long-chain fatty acid with unique chemical properties. It possesses a tridecyl group attached to a hexadecanoic acid backbone, which contributes to its distinct structure and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3-Tridecylhexadecanoic Acid is used as an active ingredient in the development of Vizantin, an immunostimulant. It plays a crucial role in enhancing the immune response and supporting the body's natural defense mechanisms against infections and diseases.
Used in Cytotoxicity Research:
3-Tridecylhexadecanoic Acid displays cytotoxic activity toward Vero cells, which are a line of cells derived from the kidney of an African green monkey. This property makes it a valuable compound for studying the mechanisms of cell death and potential applications in cancer research and treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 180476-36-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,0,4,7 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 180476-36:
(8*1)+(7*8)+(6*0)+(5*4)+(4*7)+(3*6)+(2*3)+(1*6)=142
142 % 10 = 2
So 180476-36-2 is a valid CAS Registry Number.
180476-36-2Relevant articles and documents
Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6′-dicorynomycolate
Yamamoto, Hirofumi,Oda, Masataka,Nakano, Mayo,Watanabe, Naoyuki,Yabiku, Kenta,Shibutani, Masahiro,Inoue, Masahisa,Imagawa, Hiroshi,Nagahama, Masahiro,Himeno, Seiichiro,Setsu, Kojun,Sakurai, Jun,Nishizawa, Mugio
supporting information, p. 381 - 385 (2013/02/23)
Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′- trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6′- dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.